(NOVN) Novartis - Ratings and Ratios
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0012005267
NOVN: Medicines, Therapies, Treatments, Drugs, Vaccines, Pills
Novartis AG, a global leader in the pharmaceutical industry, operates at the forefront of healthcare innovation. Specializing in the research, development, and marketing of prescription medicines, the company addresses a wide array of therapeutic areas. Notable products include Pluvicto and Lutathera, which are pivotal in treating advanced prostate cancer and neuroendocrine tumors, respectively. With a strong focus on R&D, Novartis has positioned itself as a key player in cardiovascular, immunological, and oncological treatments.
The companys strategic collaborations underscore its commitment to innovation. Partnerships with Alnylam Pharmaceuticals for inclisiran, a novel LDL cholesterol treatment, and Dawn Health for Ekiva, a digital solution targeting Paroxysmal Nocturnal Hemoglobinuria, exemplify its forward-thinking approach. Additionally, collaborations with Schrödinger and Vyriad in areas like therapeutic candidate development and CAR-T cell therapies highlight Novartiss dedication to cutting-edge science and patient-centric solutions.
From a financial standpoint, Novartis boasts a market cap of CHF 187.5 billion, reflecting its stability and market leadership. With a P/E ratio of 18.11 and a forward P/E of 12.67, the company indicates a balanced approach to growth and valuation. Its price-to-sales ratio of 3.76 underscores efficient revenue generation. These metrics, combined with its robust product pipeline and strategic collaborations, position Novartis as a compelling investment opportunity in the pharmaceutical sector.
Additional Sources for NOVN Stock
NOVN Stock Overview
| Market Cap in USD | 226,773m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
NOVN Stock Ratings
| Growth 5y | 64.8% |
| Fundamental | 71.0% |
| Dividend | 63.1% |
| Rel. Strength Industry | 14 |
| Analysts | - |
| Fair Price Momentum | 100.72 CHF |
| Fair Price DCF | 161.51 CHF |
NOVN Dividends
| Dividend Yield 12m | 3.74% |
| Yield on Cost 5y | 6.42% |
| Annual Growth 5y | 2.27% |
| Payout Consistency | 100.0% |
NOVN Growth Ratios
| Growth Correlation 3m | 92.7% |
| Growth Correlation 12m | 32.2% |
| Growth Correlation 5y | 90.2% |
| CAGR 5y | 12.02% |
| CAGR/Max DD 5y | 0.63 |
| Sharpe Ratio 12m | 0.43 |
| Alpha | 6.97 |
| Beta | 0.22 |
| Volatility | 16.73% |
| Current Volume | 4422.4k |
| Average Volume 20d | 3943.2k |
As of March 13, 2025, the stock is trading at CHF 96.31 with a total of 4,422,368 shares traded.
Over the past week, the price has changed by -0.25%, over one month by +2.00%, over three months by +13.28% and over the past year by +13.89%.
Yes, based on ValueRay Fundamental Analyses, Novartis (SW:NOVN) is currently (March 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 70.95 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NOVN as of March 2025 is 100.72. This means that NOVN is currently overvalued and has a potential downside of 4.58%.
Novartis has no consensus analysts rating.
According to ValueRays Forecast Model, NOVN Novartis will be worth about 108.9 in March 2026. The stock is currently trading at 96.31. This means that the stock has a potential upside of +13.05%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 99.7 | 3.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 108.9 | 13.1% |